T3S Technologies provides genetically engineered bacterial cells designed to expand their biologics manufacturing capabilities and dramatically shortens the current manufacturing process. The firm has developed a bacterial expression system aimed at reducing the cost of producing biologics such as insulin, fabs, filgrastim, ScFv, and Interferon ß-1b.
